24 March 2015
The Centre will focus on postgraduate research across a range of life-saving biomedical fields
A state-of-the-art biomedical research facility has been launched at the University of Central Lancashire (UCLan).
The series of high-tech laboratories have been designed to focus multi-disciplinary postgraduate research across a breadth of biomedical fields, including research in the fields of: brain tumours, anti-cancer, antibiotics, Alzheimer’s, DNA profiling and molecular biology.
Professor Bob Lea, a UCLan expert in neuroscience, said: “This fantastic new facility is all about bringing together our researchers with scientists, clinicians and health professionals who are unified in searching for new treatments and diagnostic tests for a wide range of diseases and conditions.”
Neurodegenerative diseases, cancer biology, infectious diseases, oral diseases, tissue repair and regeneration are also among the research topics which will be investigated.
Dr Sarah Dennison, the Biomedical Research Facility Laboratory Manager, added: “It’s such an exciting time for current and prospective students to be involved with biomedical science at UCLan. Ultimately it’s about conducting research to make those major scientific breakthroughs into life-saving treatments for patients.”
“UCLan is an academic leader in a host of scientific and biomedical disciplines, most recently in brain tumour research. We know this investment will continue to extend the reach and significance of our research impact.”
(From l-r Dr Sarah Dennison, Professor Charles Davis, Professor Robert Walsh and Professor Bob Lea.)
The launch event, which took place on 23 March on the Preston Campus, brought together professionals, academics and other interested bodies who could potentially work in collaboration with the University. The introduction to the facility was made by Professor Robert Walsh, Executive Director of Research, before the guests took part in a tour the laboratories.
Professor Walsh said: “Research is at the heart of everything we do at the University and this new state-of-the-art biomedical facility will further enhance our growing reputation. UCLan is an academic leader in a host of scientific and biomedical disciplines, most recently in brain tumour research. We know this investment will continue to extend the reach and significance of our research impact.”
Over the last few years UCLan researchers have worked closely, through Brain Tumour North West, the Neurosurgical Unit and Neuropathology Department at the Royal Preston Hospital, other universities and NHS institutions across the region.
Professor Charles Davis, Consultant Neurosurgeon at Lancashire Teaching Hospitals NHS Foundation Trust, said: “Biomedical research is incredibly complex; disease causing defects may be manifested at the molecular, cellular, organ and organismic level, and an understanding of the relevance of each of these demands a multidisciplinary approach requiring an extensive range of dedicated facilities and equipment. The development of the UCLan Biomedical Research Facility creates one of the best such infrastructures in the UK which will support coordinated programmes of biomedical research that will have significant impact upon our quality of life.”